158 related articles for article (PubMed ID: 10815906)
21. Clinical significance of p53, mdm2, and bcl-2 proteins in renal cell carcinoma.
Uchida T; Gao JP; Wang C; Jiang SX; Muramoto M; Satoh T; Minei S; Shimura S; Irie A; Kameya T; Baba S
Urology; 2002 Apr; 59(4):615-20. PubMed ID: 11927338
[TBL] [Abstract][Full Text] [Related]
22. p53 regulation and function in renal cell carcinoma.
Warburton HE; Brady M; Vlatković N; Linehan WM; Parsons K; Boyd MT
Cancer Res; 2005 Aug; 65(15):6498-503. PubMed ID: 16061625
[TBL] [Abstract][Full Text] [Related]
23. Expression of p53 and mdm2 and their significance in recurrence of superficial bladder cancer.
Tuna B; Yörükoğlu K; Tüzel E; Güray M; Mungan U; Kirkali Z
Pathol Res Pract; 2003; 199(5):323-8. PubMed ID: 12908522
[TBL] [Abstract][Full Text] [Related]
24. A molecular and immunohistochemical study of the MDM2 protein isoforms and p53 gene product in bronchogenic carcinoma.
Gorgoulis VG; Zoumpourlis V; Rassidakis GZ; Karameris A; Rassidakis AN; Spandidos DA; Kittas C
J Pathol; 1996 Oct; 180(2):129-37. PubMed ID: 8976869
[TBL] [Abstract][Full Text] [Related]
25. Leiomyosarcoma of the uterus: A clinicopathologic, DNA flow cytometric, p53, and mdm-2 analysis of 49 cases.
Blom R; Guerrieri C; Stâl O; Malmström H; Simonsen E
Gynecol Oncol; 1998 Jan; 68(1):54-61. PubMed ID: 9454661
[TBL] [Abstract][Full Text] [Related]
26. The prognostic value of cyclin D1, p53, and MDM2 protein expression in uveal melanoma.
Coupland SE; Anastassiou G; Stang A; Schilling H; Anagnostopoulos I; Bornfeld N; Stein H
J Pathol; 2000 Jun; 191(2):120-6. PubMed ID: 10861569
[TBL] [Abstract][Full Text] [Related]
27. p53 and MDM2 in the development and progression of bladder cancer.
Schmitz-Dräger BJ; Kushima M; Goebell P; Jax TW; Gerharz CD; Bültel H; Schulz WA; Ebert T; Ackermann R
Eur Urol; 1997; 32(4):487-93. PubMed ID: 9412812
[TBL] [Abstract][Full Text] [Related]
28. The expression of murine double minute 2 is a favorable prognostic marker in esophageal squamous cell carcinoma without p53 protein accumulation.
Saito H; Tsujitani S; Oka S; Ikeguchi M; Maeta M; Kaibara N
Ann Surg Oncol; 2002 Jun; 9(5):450-6. PubMed ID: 12052755
[TBL] [Abstract][Full Text] [Related]
29. MDM2 gene amplification and expression in non-small-cell lung cancer: immunohistochemical expression of its protein is a favourable prognostic marker in patients without p53 protein accumulation.
Higashiyama M; Doi O; Kodama K; Yokouchi H; Kasugai T; Ishiguro S; Takami K; Nakayama T; Nishisho I
Br J Cancer; 1997; 75(9):1302-8. PubMed ID: 9155050
[TBL] [Abstract][Full Text] [Related]
30. Value of p53 as a prognostic marker in histologic subtypes of renal cell carcinoma: a systematic analysis of primary and metastatic tumor tissue.
Zigeuner R; Ratschek M; Rehak P; Schips L; Langner C
Urology; 2004 Apr; 63(4):651-5. PubMed ID: 15072872
[TBL] [Abstract][Full Text] [Related]
31. p53, Mdm2, and c-Myc overexpression is associated with a poor prognosis in aggressive non-Hodgkin's lymphomas.
Pagnano KB; Vassallo J; Lorand-Metze I; Costa FF; Saad ST
Am J Hematol; 2001 Jun; 67(2):84-92. PubMed ID: 11343379
[TBL] [Abstract][Full Text] [Related]
32. p53 and mdm2 in mantle cell lymphoma in leukemic phase.
Solenthaler M; Matutes E; Brito-Babapulle V; Morilla R; Catovsky D
Haematologica; 2002 Nov; 87(11):1141-50. PubMed ID: 12414343
[TBL] [Abstract][Full Text] [Related]
33. [The expression of Mdm2 protein and p53 mutation in lung squamous cell carcinomas and their clinicopathological significance].
Zhang J; Liu H; Li S; Gu C
Zhonghua Jie He He Hu Xi Za Zhi; 1999 Mar; 22(3):163-5. PubMed ID: 11812371
[TBL] [Abstract][Full Text] [Related]
34. Overexpression of mdm2 and p53 and association with progesterone receptor expression in benign meningiomas.
Das A; Tan WL; Teo J; Smith DR
Neuropathology; 2002 Sep; 22(3):194-9. PubMed ID: 12416559
[TBL] [Abstract][Full Text] [Related]
35. Cyclooxygenase-2 and p53 expression as prognostic indicators in conventional renal cell carcinoma.
Cho DS; Joo HJ; Oh DK; Kang JH; Kim YS; Lee KB; Kim SJ
Yonsei Med J; 2005 Feb; 46(1):133-40. PubMed ID: 15744816
[TBL] [Abstract][Full Text] [Related]
36. Oncoprotein MDM2 overexpression is associated with poor prognosis in distinct non-Hodgkin's lymphoma entities.
Møller MB; Nielsen O; Pedersen NT
Mod Pathol; 1999 Nov; 12(11):1010-6. PubMed ID: 10574597
[TBL] [Abstract][Full Text] [Related]
37. Expression of bcl-2, p53 oncoprotein, and proliferating cell nuclear antigen in renal cell carcinoma.
Sejima T; Miyagawa I
Eur Urol; 1999; 35(3):242-8. PubMed ID: 10072628
[TBL] [Abstract][Full Text] [Related]
38. Mdm2 gene amplification in gastric cancer correlation with expression of Mdm2 protein and p53 alterations.
Günther T; Schneider-Stock R; Häckel C; Kasper HU; Pross M; Hackelsberger A; Lippert H; Roessner A
Mod Pathol; 2000 Jun; 13(6):621-6. PubMed ID: 10874665
[TBL] [Abstract][Full Text] [Related]
39. Significance of cell cycle regulatory proteins as malignant and prognostic biomarkers in ovarian epithelial tumors.
Lee YH; Heo JH; Kim TH; Kang H; Kim G; Kim J; Cho SH; An HJ
Int J Gynecol Pathol; 2011 May; 30(3):205-17. PubMed ID: 21464733
[TBL] [Abstract][Full Text] [Related]
40. [Correlation between Gli1 expression and clinicopathological significance in human pancreatic cancer].
Sheng WW; Dong M; Zhou JP; Liu QF; Li X; Dong Q
Zhonghua Wai Ke Za Zhi; 2013 Oct; 51(10):916-21. PubMed ID: 24433772
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
